TW202003052A - 用於治療黃斑部失養症之組成物及方法 - Google Patents
用於治療黃斑部失養症之組成物及方法 Download PDFInfo
- Publication number
- TW202003052A TW202003052A TW108112207A TW108112207A TW202003052A TW 202003052 A TW202003052 A TW 202003052A TW 108112207 A TW108112207 A TW 108112207A TW 108112207 A TW108112207 A TW 108112207A TW 202003052 A TW202003052 A TW 202003052A
- Authority
- TW
- Taiwan
- Prior art keywords
- sequence
- patent application
- sequence encoding
- cell
- aav
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 107
- 238000000034 method Methods 0.000 title claims description 60
- 208000002780 macular degeneration Diseases 0.000 title abstract description 19
- 208000035719 Maculopathy Diseases 0.000 title abstract description 11
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 claims abstract description 268
- 102100022794 Bestrophin-1 Human genes 0.000 claims abstract description 248
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims abstract description 98
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 85
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 75
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 65
- 108050002823 Bestrophin Proteins 0.000 claims abstract description 44
- 102000012304 Bestrophin Human genes 0.000 claims abstract description 43
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 34
- 108050003623 Bestrophin-1 Proteins 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 145
- 239000013598 vector Substances 0.000 claims description 85
- 239000013607 AAV vector Substances 0.000 claims description 79
- 238000002347 injection Methods 0.000 claims description 73
- 239000007924 injection Substances 0.000 claims description 73
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 65
- 239000002245 particle Substances 0.000 claims description 38
- 230000003612 virological effect Effects 0.000 claims description 33
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims description 32
- 210000002706 plastid Anatomy 0.000 claims description 28
- 239000003981 vehicle Substances 0.000 claims description 25
- 210000001525 retina Anatomy 0.000 claims description 21
- 230000035772 mutation Effects 0.000 claims description 20
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 19
- 102000049740 human BEST1 Human genes 0.000 claims description 19
- 230000002207 retinal effect Effects 0.000 claims description 19
- 241000700605 Viruses Species 0.000 claims description 18
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 14
- 108091026890 Coding region Proteins 0.000 claims description 13
- 210000005260 human cell Anatomy 0.000 claims description 13
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 12
- 210000002845 virion Anatomy 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 11
- 238000001802 infusion Methods 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 10
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 9
- 101150077415 BEST1 gene Proteins 0.000 claims description 8
- 108010087504 Beta-Globulins Proteins 0.000 claims description 8
- 241000287828 Gallus gallus Species 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 7
- 208000000509 infertility Diseases 0.000 claims description 7
- 230000036512 infertility Effects 0.000 claims description 7
- 231100000535 infertility Toxicity 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 6
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 6
- 108700005077 Viral Genes Proteins 0.000 claims description 6
- 108010006025 bovine growth hormone Proteins 0.000 claims description 6
- 210000000608 photoreceptor cell Anatomy 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 5
- 241000202702 Adeno-associated virus - 3 Species 0.000 claims description 5
- 241000580270 Adeno-associated virus - 4 Species 0.000 claims description 5
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 5
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims description 5
- 241000702421 Dependoparvovirus Species 0.000 claims description 5
- 210000002969 egg yolk Anatomy 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 108010085238 Actins Proteins 0.000 claims description 4
- 241001164823 Adeno-associated virus - 7 Species 0.000 claims description 4
- 241000649045 Adeno-associated virus 10 Species 0.000 claims description 4
- 241000649046 Adeno-associated virus 11 Species 0.000 claims description 4
- 241000283984 Rodentia Species 0.000 claims description 4
- 230000008488 polyadenylation Effects 0.000 claims description 4
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 230000001124 posttranscriptional effect Effects 0.000 claims description 3
- 230000000392 somatic effect Effects 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241000009328 Perro Species 0.000 claims description 2
- 241000700159 Rattus Species 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 210000004498 neuroglial cell Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims 3
- 241000555745 Sciuridae Species 0.000 claims 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 10
- 210000001508 eye Anatomy 0.000 description 53
- 230000014509 gene expression Effects 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 21
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 16
- 108090000565 Capsid Proteins Proteins 0.000 description 13
- 102100023321 Ceruloplasmin Human genes 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 239000013603 viral vector Substances 0.000 description 13
- 239000010410 layer Substances 0.000 description 12
- 238000012014 optical coherence tomography Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000001262 western blot Methods 0.000 description 12
- 101710147147 Dystrophin-1 Proteins 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 108091092195 Intron Proteins 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 241000701022 Cytomegalovirus Species 0.000 description 8
- 210000003161 choroid Anatomy 0.000 description 8
- 229960004679 doxorubicin Drugs 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 7
- 210000000234 capsid Anatomy 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 108091008695 photoreceptors Proteins 0.000 description 7
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 208000024304 Choroidal Effusions Diseases 0.000 description 5
- 108700024394 Exon Proteins 0.000 description 5
- 210000005252 bulbus oculi Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 4
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 4
- 206010025421 Macule Diseases 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003889 eye drop Substances 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000003994 retinal ganglion cell Anatomy 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 101150044789 Cap gene Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010038848 Retinal detachment Diseases 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000004264 retinal detachment Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- BFUUJUGQJUTPAF-UHFFFAOYSA-N 2-(3-amino-4-propoxybenzoyl)oxyethyl-diethylazanium;chloride Chemical compound [Cl-].CCCOC1=CC=C(C(=O)OCC[NH+](CC)CC)C=C1N BFUUJUGQJUTPAF-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101100412102 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) rec2 gene Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 2
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 2
- 102100037935 Polyubiquitin-C Human genes 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 2
- 108010056354 Ubiquitin C Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000001775 bruch membrane Anatomy 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 231100000683 possible toxicity Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229960003981 proparacaine Drugs 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 101150066583 rep gene Proteins 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 1
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 1
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 1
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 1
- 241000958487 Adeno-associated virus 3B Species 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100037377 DNA-(apurinic or apyrimidinic site) endonuclease 2 Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 101000806823 Homo sapiens DNA-(apurinic or apyrimidinic site) endonuclease 2 Proteins 0.000 description 1
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108050001370 Tight junction protein ZO-1 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 208000036866 Vitreoretinopathy Diseases 0.000 description 1
- 102000044820 Zonula Occludens-1 Human genes 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 description 1
- 229960003002 atipamezole Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 101150095935 cba gene Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 239000012792 core layer Substances 0.000 description 1
- 238000011018 current good manufacturing practice Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Manufacturing & Machinery (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862653131P | 2018-04-05 | 2018-04-05 | |
| US62/653,131 | 2018-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202003052A true TW202003052A (zh) | 2020-01-16 |
Family
ID=66223872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108112207A TW202003052A (zh) | 2018-04-05 | 2019-04-08 | 用於治療黃斑部失養症之組成物及方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20190307900A1 (enExample) |
| EP (1) | EP3775233A1 (enExample) |
| JP (1) | JP2021520232A (enExample) |
| KR (1) | KR20210005040A (enExample) |
| CN (1) | CN113056561A (enExample) |
| AU (1) | AU2019247864A1 (enExample) |
| BR (1) | BR112020020204A2 (enExample) |
| CA (1) | CA3096088A1 (enExample) |
| CL (1) | CL2020002561A1 (enExample) |
| CO (1) | CO2020013690A2 (enExample) |
| EA (1) | EA202092069A1 (enExample) |
| IL (1) | IL277779A (enExample) |
| JO (1) | JOP20200253A1 (enExample) |
| MA (1) | MA52199A (enExample) |
| MX (1) | MX2020010477A (enExample) |
| PE (1) | PE20210918A1 (enExample) |
| PH (1) | PH12020551641A1 (enExample) |
| RU (1) | RU2020132890A (enExample) |
| SG (1) | SG11202009759SA (enExample) |
| TW (1) | TW202003052A (enExample) |
| WO (1) | WO2019195727A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111849998A (zh) * | 2020-07-29 | 2020-10-30 | 武汉纽福斯生物科技有限公司 | 编码人卵黄状黄斑病蛋白1的核酸分子及其应用 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020047476A1 (en) * | 2018-08-31 | 2020-03-05 | University Of Florida Research Foundation, Incorporated | Adeno-associated viral vectors for the treatment of best disease |
| EP3870148A4 (en) | 2018-10-25 | 2022-11-09 | Takeda Pharmaceutical Company Limited | AAV TRIPLE PLASMID SYSTEM |
| WO2020140007A1 (en) * | 2018-12-28 | 2020-07-02 | University Of Rochester | Gene therapy for best1 dominant mutations |
| BR112022017182A2 (pt) * | 2020-02-28 | 2022-11-08 | Univ Pennsylvania | Tratamento de bestrofinopatias autossômicas recessivas e métodos para avaliação das mesmas |
| WO2024064608A2 (en) * | 2022-09-20 | 2024-03-28 | Intergalactic Therapeutics, Inc. | Best1 vectors and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009153563A1 (en) * | 2008-06-18 | 2009-12-23 | Oxford Biomedica (Uk) Limited | Virus purification |
| US9163259B2 (en) * | 2012-05-04 | 2015-10-20 | Novartis Ag | Viral vectors for the treatment of retinal dystrophy |
| CA2930282C (en) * | 2013-11-20 | 2024-09-10 | Universita Degli Studi Di Napoli Federico Ii | Artificial DNA-Binding Proteins and Their Uses |
| KR102281881B1 (ko) * | 2013-12-06 | 2021-07-27 | 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) | 대상체의 망막 색소 상피에서 목적 폴리뉴클레오티드를 발현시키기 위한 방법 및 약학적 조성물 |
| GB201322798D0 (en) * | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
| CA2979120A1 (en) * | 2015-03-03 | 2016-09-09 | Fondazione Telethon | Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof |
| EP3374494A4 (en) * | 2015-11-11 | 2019-05-01 | Coda Biotherapeutics, Inc. | CRISPR COMPOSITIONS AND METHODS OF USE THEREOF FOR GENE THERAPY |
-
2019
- 2019-04-05 BR BR112020020204-5A patent/BR112020020204A2/pt not_active Application Discontinuation
- 2019-04-05 WO PCT/US2019/026062 patent/WO2019195727A1/en not_active Ceased
- 2019-04-05 EA EA202092069A patent/EA202092069A1/ru unknown
- 2019-04-05 CA CA3096088A patent/CA3096088A1/en not_active Withdrawn
- 2019-04-05 MA MA052199A patent/MA52199A/fr unknown
- 2019-04-05 JP JP2021504131A patent/JP2021520232A/ja not_active Withdrawn
- 2019-04-05 EP EP19718557.2A patent/EP3775233A1/en not_active Withdrawn
- 2019-04-05 MX MX2020010477A patent/MX2020010477A/es unknown
- 2019-04-05 PE PE2020001530A patent/PE20210918A1/es unknown
- 2019-04-05 US US16/376,808 patent/US20190307900A1/en not_active Abandoned
- 2019-04-05 CN CN201980031769.0A patent/CN113056561A/zh not_active Withdrawn
- 2019-04-05 JO JOP/2020/0253A patent/JOP20200253A1/ar unknown
- 2019-04-05 KR KR1020207031540A patent/KR20210005040A/ko not_active Withdrawn
- 2019-04-05 RU RU2020132890A patent/RU2020132890A/ru unknown
- 2019-04-05 AU AU2019247864A patent/AU2019247864A1/en not_active Abandoned
- 2019-04-05 SG SG11202009759SA patent/SG11202009759SA/en unknown
- 2019-04-08 TW TW108112207A patent/TW202003052A/zh unknown
-
2020
- 2020-10-02 CL CL2020002561A patent/CL2020002561A1/es unknown
- 2020-10-04 IL IL277779A patent/IL277779A/en unknown
- 2020-10-05 PH PH12020551641A patent/PH12020551641A1/en unknown
- 2020-10-30 CO CONC2020/0013690A patent/CO2020013690A2/es unknown
-
2022
- 2022-09-15 US US17/945,344 patent/US20230149566A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111849998A (zh) * | 2020-07-29 | 2020-10-30 | 武汉纽福斯生物科技有限公司 | 编码人卵黄状黄斑病蛋白1的核酸分子及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3775233A1 (en) | 2021-02-17 |
| AU2019247864A1 (en) | 2020-10-22 |
| WO2019195727A1 (en) | 2019-10-10 |
| MA52199A (fr) | 2021-02-17 |
| BR112020020204A2 (pt) | 2021-01-19 |
| PE20210918A1 (es) | 2021-05-19 |
| US20190307900A1 (en) | 2019-10-10 |
| JP2021520232A (ja) | 2021-08-19 |
| IL277779A (en) | 2020-11-30 |
| PH12020551641A1 (en) | 2021-07-26 |
| US20230149566A1 (en) | 2023-05-18 |
| MX2020010477A (es) | 2021-03-02 |
| JOP20200253A1 (ar) | 2020-10-04 |
| CL2020002561A1 (es) | 2021-04-23 |
| SG11202009759SA (en) | 2020-10-29 |
| CN113056561A (zh) | 2021-06-29 |
| RU2020132890A (ru) | 2022-05-06 |
| KR20210005040A (ko) | 2021-01-13 |
| CA3096088A1 (en) | 2019-10-10 |
| CO2020013690A2 (es) | 2021-04-19 |
| EA202092069A1 (ru) | 2021-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2987337T3 (es) | Composiciones y métodos para reducir la neovascularización ocular | |
| JP2022107042A (ja) | ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法 | |
| JP2022037158A (ja) | 錐体細胞における増強された遺伝子発現のための組成物および方法 | |
| JP6827320B2 (ja) | ＬＣＡ−８及び進行性ＲＰを治療するための組換えＡＡＶ−Ｃｒｕｍｂｓホモログ組成物及び方法 | |
| ES2826384T3 (es) | Terapia génica para trastornos oculares | |
| US12467066B2 (en) | Compositions and methods for treating retinal disorders | |
| JP2022106918A (ja) | Ｒｄｈ１２が関与する疾患及び疾病を治療する方法及び組成物 | |
| JP2021520232A (ja) | 黄斑ジストロフィーを処置するための組成物及び方法 | |
| US20230338582A1 (en) | Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy | |
| BR112019017327A2 (pt) | terapia gênica para distúrbios oculares | |
| JP2023544803A (ja) | Ｃｌｎ２疾患の眼症状に対する遺伝子療法 | |
| CN113795279B (zh) | 靶向akt通路的神经保护性基因疗法 | |
| WO2023285987A1 (en) | Retgc gene therapy | |
| JP2021520231A (ja) | シュタルガルト病の処置のための組成物及び方法 | |
| US20240124893A1 (en) | Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy | |
| Fehrman | Feasibility of Large Transgene Delivery to the Mouse Retina: Eyeing the Potential for Gene Therapy Applications | |
| HK40066183A (en) | Neuroprotective gene therapy targeting the akt pathway | |
| HK40066183B (en) | Neuroprotective gene therapy targeting the akt pathway | |
| EP4262882A1 (en) | Gene therapy for treating usher syndrome | |
| HK40013460A (en) | Methods and compositions for treatment of disorders and diseases involving rdh12 | |
| HK40013460B (zh) | 用於治疗涉及rdh12的病症和疾病的方法和组合物 |